Canadian Journal of Neurological Sciences最新文献_第8页

An Anatomical Perspective to Botulinum Toxin Injection of Flexor Digitorum Profundus. 从解剖学角度看屈指深肌的肉毒杆菌毒素注射。

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-03-11 DOI: 10.1017/cjn.2024.34

Emma Stefanie Campisi, Omar Khan, Anne Marie Reet Agur, Rajiv Reebye

引用次数: 0

Cough Headache Responsive to Occipital Nerve Blockade. 对枕神经阻断术有反应的咳嗽性头痛

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-03-11 DOI: 10.1017/cjn.2024.17

Aqeel Almutairi, Tommy Lik Hang Chan

引用次数: 0

Atypical Bilateral Idiopathic Inflammatory Cavernous Sinus Syndrome Responsive to Cyclophosphamide. 对环磷酰胺有反应的非典型双侧特发性炎性海绵窦综合征

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-03-06 DOI: 10.1017/cjn.2024.29

Nabeela Nathoo, Kevin D Chodnicki, Jamie J Van Gompel, Karl N Krecke, Aivi T Nguyen, Michel Toledano, Orhun H Kantarci

引用次数: 0

Poststroke Care Pathways and Spasticity Treatment: A Retrospective Study in Alberta. 中风后护理路径和痉挛治疗：艾伯塔省的一项回顾性研究。

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-03-22 DOI: 10.1017/cjn.2024.42

Lalith Satkunam, Sean P Dukelow, Jaime Yu, Stephen McNeil, Huong Luu, Karen J B Martins, Khanh Vu, Phuong Uyen Nguyen, Lawrence Richer, Tyler Williamson, Scott W Klarenbach

{"title":"Poststroke Care Pathways and Spasticity Treatment: A Retrospective Study in Alberta.","authors":"Lalith Satkunam, Sean P Dukelow, Jaime Yu, Stephen McNeil, Huong Luu, Karen J B Martins, Khanh Vu, Phuong Uyen Nguyen, Lawrence Richer, Tyler Williamson, Scott W Klarenbach","doi":"10.1017/cjn.2024.42","DOIUrl":"10.1017/cjn.2024.42","url":null,"abstract":"Background: Limited evidence exists regarding care pathways for stroke survivors who do and do not receive poststroke spasticity (PSS) treatment.Methods: Administrative data was used to identify adults who experienced a stroke and sought acute care between 2012 and 2017 in Alberta, Canada. Pathways of stroke care within the health care system were determined among those who initiated PSS treatment (PSS treatment group: outpatient pharmacy dispensation of an anti-spastic medication, focal chemo-denervation injection, or a spasticity tertiary clinic visit) and those who did not (non-PSS treatment group). Time from the stroke event until spasticity treatment initiation, and setting where treatment was initiated were reported. Descriptive statistics were performed.Results: Health care settings within the pathways of stroke care that the PSS (n = 1,079) and non-PSS (n = 22,922) treatment groups encountered were the emergency department (86 and 84%), acute inpatient care (80 and 69%), inpatient rehabilitation (40 and 12%), and long-term care (19 and 13%), respectively. PSS treatment was initiated a median of 291 (interquartile range 625) days after the stroke event, and most often in the community when patients were residing at home (45%), followed by \"other\" settings (22%), inpatient rehabilitation (18%), long-term care (11%), and acute inpatient care (4%).Conclusions: To our knowledge, this is the first population based cohort study describing pathways of care among adults with stroke who subsequently did or did not initiate spasticity treatment. Areas for improvement in care may include strategies for earlier identification and treatment of PSS.","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"75-84"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140186407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Yoga as an Add-on Therapy in Parkinson's Disease: A Single Group Open-label Trial. 瑜伽作为帕金森病的附加疗法：单组开放标签试验

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-03-25 DOI: 10.1017/cjn.2024.43

Pooja Mailankody, Nitish Kamble, Amitabh Bhattacharya, G S Shubha Bhat, Thamodharan Arumugam, K Thennarasu, Rashmi Arasappa, Shivarama Varambally, Ravi Yadav, Pramod Kumar Pal

{"title":"Yoga as an Add-on Therapy in Parkinson's Disease: A Single Group Open-label Trial.","authors":"Pooja Mailankody, Nitish Kamble, Amitabh Bhattacharya, G S Shubha Bhat, Thamodharan Arumugam, K Thennarasu, Rashmi Arasappa, Shivarama Varambally, Ravi Yadav, Pramod Kumar Pal","doi":"10.1017/cjn.2024.43","DOIUrl":"10.1017/cjn.2024.43","url":null,"abstract":"Objective: We aimed to evaluate the effect of yoga on motor and non-motor symptoms and cortical excitability in patients with Parkinson's disease (PD).Methods: We prospectively evaluated 17 patients with PD at baseline, after one month of conventional care, and after one month of supervised yoga sessions. The motor and non-motor symptoms were evaluated using the Unified Parkinson's disease Rating Scale (motor part III), Hoehn and Yahr stage, Montreal Cognitive Assessment, Hamilton depression rating scale, Hamilton anxiety rating scale, non-motor symptoms questionnaire and World Health Organization quality of life questionnaire. Transcranial magnetic stimulation was used to record resting motor threshold, central motor conduction time, ipsilateral silent period (iSP), contralateral silent period (cSP), short interval intracortical inhibition (SICI), and intracortical facilitation.Results: The mean age of the patients was 55.5 ± 10.8 years, with a mean duration of illness of 4.0 ± 2.5 years. The postural stability of the patients significantly improved following yoga (0.59 ± 0.5 to 0.18 ± 0.4, p = 0.039). There was a significant reduction in the cSP from baseline (138.07 ± 27.5 ms) to 4 weeks of yoga therapy (116.94 ± 18.2 ms, p = 0.004). In addition, a significant reduction in SICI was observed after four weeks of yoga therapy (0.22 ± 0.10) to (0.46 ± 0.23), p = 0.004).Conclusion: Yoga intervention can significantly improve postural stability in patients with PD. A significant reduction of cSP and SICI suggests a reduction in GABAergic neurotransmission following yoga therapy that may underlie the improvement observed in postural stability.Clinicaltrialsgov identifier: CTRI/2019/02/017564.","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"102-109"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140208368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Real-World Study of Nusinersen Effects in Adults with Spinal Muscular Atrophy Type 2 and 3. 对患有脊髓性肌肉萎缩症 2 型和 3 型的成人进行的一项有关 Nusinersen 效果的真实世界研究。

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-03-27 DOI: 10.1017/cjn.2024.49

Isabelle Côté, Victoria Hodgkinson, Marianne Nury, Louis Bastenier-Boutin, Xavier Rodrigue

{"title":"A Real-World Study of Nusinersen Effects in Adults with Spinal Muscular Atrophy Type 2 and 3.","authors":"Isabelle Côté, Victoria Hodgkinson, Marianne Nury, Louis Bastenier-Boutin, Xavier Rodrigue","doi":"10.1017/cjn.2024.49","DOIUrl":"10.1017/cjn.2024.49","url":null,"abstract":"Background: Spinal muscular atrophy (SMA) is a progressive genetic disorder characterized by muscle weakness ultimately leading to pulmonary impairments that can be fatal. The recent approval of nusinersen, a disease-modifying therapy, substantially changed the prognosis for patients, particularly in children. However, real-world evidence about its long-term effectiveness in adults remains limited. This study aimed to document longitudinal data on motor function, pulmonary function and patient-reported outcome measures of Canadian adults with SMA type 2 and 3 treated with nusinersen.Methods: Outcomes from 17 patients were collected at the Institut de réadaptation en déficience physique de Québec during routine clinical visits over 36 months post nusinersen treatment, using the Hammersmith Functional Motor Scale Expanded for SMA (HFMSE), Revised Upper Limb Module (RULM), 6-Minute Walk Test (6MWT), Children's Hospital of Philadelphia Adult Test of Neuromuscular Disorders (CHOP-ATEND), SMA functional rating scale (SMAFRS), pulmonary function testing and subjective changes reported by patients.Results: After 36 months, 9 patients showed motor function improvement. Changes beyond the minimal clinically important difference were seen for four patients on the HFMSE, four patients on the RULM and five patients on the 6MWT. Pulmonary function remained stable for most subjects. Subjective positive changes were reported in 88% of patients and five patients showed improvement in the SMAFRS.Conclusion: This real-world study demonstrates the positive effects of nusinersen in adults with SMA types 2 and 3. Although stabilizing the patient's condition is considered therapeutic success, this study shows an improvement in motor function and subjective gains in several patients.","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"119-128"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140295383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contrast-Induced Encephalopathy and the Blood-Brain Barrier. 造影剂诱发脑病与血脑屏障

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-03-08 DOI: 10.1017/cjn.2024.38

Mark A Maclean, Patrick S Rogers, Jamil H Muradov, Gwynedd E Pickett, Alon Friedman, Adrienne Weeks, Ryan Greene, David Volders

{"title":"Contrast-Induced Encephalopathy and the Blood-Brain Barrier.","authors":"Mark A Maclean, Patrick S Rogers, Jamil H Muradov, Gwynedd E Pickett, Alon Friedman, Adrienne Weeks, Ryan Greene, David Volders","doi":"10.1017/cjn.2024.38","DOIUrl":"10.1017/cjn.2024.38","url":null,"abstract":"Background: Contrast-induced encephalopathy (CIE) is an adverse event associated with diagnostic and therapeutic endovascular procedures. Decades of animal and human research support a mechanistic role for pathological blood-brain barrier dysfunction (BBBd). Here, we describe an institutional case series and review the literature supporting a mechanistic role for BBBd in CIE.Methods: A literature review was conducted by searching MEDLINE, Web of Science, Embase, CINAHL and Cochrane databases from inception to January 31, 2022. We searched our institutional neurovascular database for cases of CIE following endovascular treatment of cerebrovascular disease during a 6-month period. Informed consent was obtained in all cases.Results: Review of the literature revealed risk factors for BBBd and CIE, including microvascular disease, pathological neuroinflammation, severe procedural hypertension, iodinated contrast load and altered cerebral blood flow dynamics. In our institutional series, 6 of 52 (11.5%) of patients undergoing therapeutic neuroendovascular procedures developed CIE during the study period. Four patients were treated for ischemic stroke and two patients for recurrent cerebral aneurysms. Mechanical stenting or thrombectomy were utilized in all cases.Conclusion: In this institutional case series and literature review of animal and human data, we identified numerous shared risk factors for CIE and BBBd, including microvascular disease, increased procedure length, large contrast volumes, severe intraoperative hypertension and use of mechanical devices that may induce iatrogenic endothelial injury.","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"85-94"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140061381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PET Imaging in Dementia: Mini-Review and Canadian Perspective for Clinical Use. 痴呆症的 PET 成像：微型综述和加拿大的临床应用前景。

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-03-04 DOI: 10.1017/cjn.2024.31

Freimut Juengling, Frank Wuest, Ralf Schirrmacher, Jonathan Abele, Alexander Thiel, Jean-Paul Soucy, Richard Camicioli, Valentina Garibotto

{"title":"PET Imaging in Dementia: Mini-Review and Canadian Perspective for Clinical Use.","authors":"Freimut Juengling, Frank Wuest, Ralf Schirrmacher, Jonathan Abele, Alexander Thiel, Jean-Paul Soucy, Richard Camicioli, Valentina Garibotto","doi":"10.1017/cjn.2024.31","DOIUrl":"10.1017/cjn.2024.31","url":null,"abstract":"PET imaging is increasingly recognized as an important diagnostic tool to investigate patients with cognitive disturbances of possible neurodegenerative origin. PET with 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG), assessing glucose metabolism, provides a measure of neurodegeneration and allows a precise differential diagnosis among the most common neurodegenerative diseases, such as Alzheimer's disease, frontotemporal dementia or dementia with Lewy bodies. PET tracers specific for the pathological deposits characteristic of different neurodegenerative processes, namely amyloid and tau deposits typical of Alzheimer's Disease, allow the visualization of these aggregates in vivo. [18F]FDG and amyloid PET imaging have reached a high level of clinical validity and are since 2022 investigations that can be offered to patients in standard clinical care in most of Canada.This article will briefly review and summarize the current knowledge on these diagnostic tools, their integration into diagnostic algorithms as well as perspectives for future developments.","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"26-38"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140023484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disparities In Drug-Resistant Epilepsy Care In Canada. 加拿大抗药性癫痫护理中的差异。

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-04-11 DOI: 10.1017/cjn.2024.57

R Grace Couper, Tresah Antaya, Dang K Nguyen, Jorge G Burneo

引用次数: 0

Colpocephaly and Partial Agenesis of Corpus Callosum with High Neurodegenerative Marker Levels. 无头畸形和胼胝体部分缺失，神经退行性标志物水平较高。

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-03-01 DOI: 10.1017/cjn.2024.22

Abrar Ahmed, Simrika Thapa, Anna Vasilevskaya, Paula Alcaide-Leon, Maria Carmela Tartaglia

引用次数: 0